Avalo Therapeutics Q3 net loss $30.6M; completes Phase 2 LOTUS enrollment for AVTX-009

Avalo Therapeutics, Inc.

2025-Q3 EPS reported -$5.47

Completed enrollment in Phase 2 LOTUS trial (~250 adults) for AVTX-009 in hidradenitis suppurativa; topline data expected mid-2026.
Cash and short-term investments $111.6M as of Sept 30, 2025; expected to fund operations into 2028.
Net loss $30.6M in Q3 2025 vs net income $23.0M in Q3 2024; basic diluted EPS -$2.19.
R&D expenses $13.6M (up $4.1M YoY) driven by LOTUS trial; G&A $5.6M (up $1.3M).
Appointed Kevin Lind to Board; expanded leadership with new Chief Business Officer and SVP HR.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.